In this issue of The Lancet Oncology, Jürgen Wolf and colleagues1 report the final clinical and biomarker results of the phase 2 GEOMETRY mono-1 trial of capmatinib, a type 1b MET inhibitor, in 160 patients with MET exon 14-mutated advanced or metastatic non-small-cell lung cancer (NSCLC). Among the 60 patients in the first-line setting, the overall response rate was 68% (95% CI 55·0–79·7), median progression-free survival was 12·5 months (95% CI 8·3–18·0), and median overall survival was 21·4 months (95% CI 15·2–30·5).